Skip to main content
TipRanks
Go Ultimate75% OFF

Restart Life Sciences (HN30) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Restart Life Sciences has a market cap or net worth of EUR 2.58M. The enterprise value is EUR 4.75M.

Market Cap
EUR 2.58M
Enterprise Value
EUR 4.75M

Share Statistics

Restart Life Sciences has 62,506,542 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
62,506,542
Owned by Insiders
13.94%
Owned by Institutions
―

Financial Efficiency

Restart Life Sciences’s return on equity (ROE) is -1.08 and return on invested capital (ROIC) is -87.79%.

Return on Equity (ROE)
-1.08
Return on Assets (ROA)
-0.79
Return on Invested Capital (ROIC)
-87.79%
Return on Capital Employed (ROCE)
-1.05
Revenue Per Employee
0
Profits Per Employee
-463.51K
Employee Count
3
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Restart Life Sciences is -1.59. Restart Life Sciences’s PEG ratio is 0.19.

PE Ratio
-1.59
PS Ratio
8.72
PB Ratio
2.98
Price to FCF
-4.13
Price to Operating Cash Flow
-4.01
PEG Ratio
0.19

Income Statement

In the last 12 months, Restart Life Sciences had revenue of 0 and earned -1.39M in profits. Earnings per share was -0.04.

Revenue
0
Gross Profit
0
Operating Income
-1.35M
Pretax Income
-1.39M
Net Income
-1.39M
EBITDA
-1.34M
Earnings Per Share (EPS)
-0.04

Cash Flow

In the last 12 months, operating cash flow was -906.33K and capital expenditures 0, giving a free cash flow of -906.33K billion.

Operating Cash Flow
-906.33K
Free Cash Flow
-906.33K
Free Cash Flow per Share
-0.02

Dividends & Yields

Restart Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-24.22%
Earnings Yield
-43.33%

Stock Price Statistics

Beta
1.30
52-Week Price Change
-37.93%
50-Day Moving Average
0.04
200-Day Moving Average
0.05
Relative Strength Index (RSI)
43.01
Average Volume (3m)
―

Important Dates

Restart Life Sciences upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).

Last Earnings Date
Aug 27, 2026
Next Earnings Date
Dec 02, 2026
Ex-Dividend Date
―

Financial Position

Restart Life Sciences as a current ratio of 3.67, with Debt / Equity ratio of 19.06%

Current Ratio
3.67
Quick Ratio
3.67
Debt to Market Cap
0.06
Net Debt to EBITDA
1.01
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Restart Life Sciences has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Restart Life Sciences EV to EBITDA ratio is -2.23, with an EV/FCF ratio of -3.84.

EV to Sales
8.10
EV to EBITDA
-2.23
EV to Free Cash Flow
-3.84
EV to Operating Cash Flow
-3.84

Balance Sheet

Restart Life Sciences has EUR 762.36K in cash and marketable securities with EUR 348.35K in debt, giving a net cash position of EUR 414.02K billion.

Cash & Marketable Securities
EUR 762.36K
Total Debt
EUR 348.35K
Net Cash
EUR 414.02K
Net Cash Per Share
EUR 0.01
Tangible Book Value Per Share
EUR 0.01

Margins

Gross margin is -175.04%, with operating margin of -365.86%, and net profit margin of -367.41%.

Gross Margin
-175.04%
Operating Margin
-365.86%
Pretax Margin
-367.41%
Net Profit Margin
-367.41%
EBITDA Margin
-362.82%
EBIT Margin
-365.86%

Analyst Forecast

The average price target for Restart Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
-457.14%